Case Number 115082 - Composition and Method of Treating Hepatitis C Virus Infection with CCR5 Inhibitors
Contact: Jill Uhl
Description: Dr. Ken Sherman has discovered that hepatitis C virus replication can be inhibited by antagonists of the CCR5 receptor which suggests its potential use as an antiviral therapy for this disease and may comprise a new class of treatment agents for hepatitis C virus infection.
Some anticipated advantages regarding clinical application of antagonists of the CCR5 receptor over the current state of the art include:
1) Classic resistance mechanisms may not be active with this new class of agents.
2) Current drugs for treatment of most common forms of hepatitis C virus infection are very expensive and this new treatment is expected to be less expensive.
The inventors hope this new technology will be developed into a line therapy option used in treatment of HCV infections after undergoing further clinical development.
The market for the proposed invention is the hepatitis C therapeutics market. Globally, about 130 million to 150 million people have chronic hepatitis C infection. A large number of those who are chronically infected will develop liver cirrhosis or liver cancer. Approximately 350,000 to 500,000 individuals die annually from hepatitis C related liver diseases. The global hepatitis C therapeutics market was valued at $5.7 billion in 2012 and is expected to grow to $18.6 billion by 2019 at a Compound Annual Growth Rate (CAGR) of 18.5%.
US Provisional Patent: 62/143,938